The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
Microbiotica Raises $48 Million Series C to Advance Pipeline into Phase 2 Clinical Development• Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment• Claude Discovers Novel Enzyme System with CRISPR-like Repeats• New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia• MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health•

Category: Clinical & Manufacturing

Whitepaper: Oral Drug Delivery of Live Biotherapeutics: From Development to Clinical Trial with EUDRACAP® Select
Clinical & Manufacturing

Whitepaper: Oral Drug Delivery of Live Biotherapeutics: From Development to Clinical Trial with EUDRACAP® Select

NOV 19, 2025
Siolta Therapeutics Reports Positive Phase 2 Results from the ADORED Study
Clinical & Manufacturing

Siolta Therapeutics Reports Positive Phase 2 Results from the ADORED Study

NOV 17, 2025
Concerto Biosciences Announces Positive Topline Results from Phase 1b Clinical Trial of ENS-002 in Patients with Atopic Dermatitis
Clinical & Manufacturing

Concerto Biosciences Announces Positive Topline Results from Phase 1b Clinical Trial of ENS-002 in Patients with Atopic Dermatitis

OCT 29, 2025
Bloom Science Demonstrates Durable Weight Loss in Overweight Individuals in Phase 1 Trial of BL-001 
Clinical & Manufacturing

Bloom Science Demonstrates Durable Weight Loss in Overweight Individuals in Phase 1 Trial of BL-001 

MAR 7, 2025
Hervé Affagard talks Phase 3 results, the regulatory landscape and industry collaborations
Clinical & Manufacturing

Hervé Affagard talks Phase 3 results, the regulatory landscape and industry collaborations

FEB 20, 2025
Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine
Clinical & Manufacturing

Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine

JAN 27, 2025
MaaT Pharma Announces Positive Results from Pivotal Phase 3 ARES Study
Clinical & Manufacturing

MaaT Pharma Announces Positive Results from Pivotal Phase 3 ARES Study

JAN 8, 2025
Microbio Announces Promising Results of “MS-20” in Combination with Keytruda for Non-Small Cell Lung Cancer
Clinical & Manufacturing

Microbio Announces Promising Results of “MS-20” in Combination with Keytruda for Non-Small Cell Lung Cancer

DEC 17, 2024
IBT’s phase III study shows a significant reduction in the secondary endpoint, all-cause mortality
Clinical & Manufacturing

IBT’s phase III study shows a significant reduction in the secondary endpoint, all-cause mortality

SEP 4, 2024
Phage lysin compound HY-133: Start of clinical phase I “first-in-human” study to eliminate Staphylococcus aureus
Clinical & Manufacturing

Phage lysin compound HY-133: Start of clinical phase I “first-in-human” study to eliminate Staphylococcus aureus

SEP 1, 2024
EUDRACAP® Select for oral targeting of sensitive microbiome: a case from development of functional coated capsule to clinical trial phase 1b
Clinical & Manufacturing

EUDRACAP® Select for oral targeting of sensitive microbiome: a case from development of functional coated capsule to clinical trial phase 1b

JUN 6, 2024